FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a monoclonal antibody that binds to tetanus toxin, use of a monoclonal antibody in the manufacture of a drug for preventing or treating tetanus and a method for preventing or treating tetanus, involving administering said monoclonal antibody to a subject. In one embodiment, the monoclonal antibody comprises a heavy chain variable region amino acid sequence selected from SEQ ID NO: 15–17, and the amino acid sequence of the light chain variable region SEQ ID NO: 18.
EFFECT: invention extends the range of tetanus toxin-binding agents.
4 cl, 9 dwg, 2 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
